Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy Burgess

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Midwives|June 7, 2014
DoulasTracy Burgess
American Heart Journal|March 20, 2012
Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging studyChristie M Ballantyne, Michael Miller, Eric J Niesor, et al.
European Heart Journal|January 26, 2010
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trialEvan A Stein, Eli M Roth, James M Rhyne, et al.
Antimicrobial Agents and Chemotherapy|November 15, 2017
Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a Randomized Trial To Prevent Cytomegalovirus Infection in High-Risk Kidney Transplant RecipientsRong Deng, Yehong Wang, Mauricio Maia, et al.
Pulmonary Therapy|February 7, 2020
An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)Mark H Gotfried, Carlos E Girod, Danielle Antin-Ozerkis, et al.
Clinical Pharmacokinetics|June 23, 2017
Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized TrialRong Deng, Ai Ping Lee, Mauricio Maia, et al.
The American Journal of Cardiology|July 7, 2009
Safety and tolerability of dalcetrapibEvan A Stein, Erik S G Stroes, George Steiner, et al.
American Heart Journal|August 13, 2011
Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomographyZahi A Fayad, Venkatesh Mani, Mark Woodward, et al.
Antimicrobial Agents and Chemotherapy|June 10, 2015
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy AdultsJulie H Ishida, Tracy Burgess, Michael A Derby, et al.
Antimicrobial Agents and Chemotherapy|July 7, 2016
Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy VolunteersJeremy J Lim, Rong Deng, Michael A Derby, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Midwives|June 7, 2014
DoulasTracy Burgess
American Heart Journal|March 20, 2012
Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging studyChristie M Ballantyne, Michael Miller, Eric J Niesor, et al.
European Heart Journal|January 26, 2010
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trialEvan A Stein, Eli M Roth, James M Rhyne, et al.
Antimicrobial Agents and Chemotherapy|November 15, 2017
Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a Randomized Trial To Prevent Cytomegalovirus Infection in High-Risk Kidney Transplant RecipientsRong Deng, Yehong Wang, Mauricio Maia, et al.
Pulmonary Therapy|February 7, 2020
An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)Mark H Gotfried, Carlos E Girod, Danielle Antin-Ozerkis, et al.
Clinical Pharmacokinetics|June 23, 2017
Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized TrialRong Deng, Ai Ping Lee, Mauricio Maia, et al.
The American Journal of Cardiology|July 7, 2009
Safety and tolerability of dalcetrapibEvan A Stein, Erik S G Stroes, George Steiner, et al.
American Heart Journal|August 13, 2011
Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomographyZahi A Fayad, Venkatesh Mani, Mark Woodward, et al.
Antimicrobial Agents and Chemotherapy|June 10, 2015
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy AdultsJulie H Ishida, Tracy Burgess, Michael A Derby, et al.
Antimicrobial Agents and Chemotherapy|July 7, 2016
Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy VolunteersJeremy J Lim, Rong Deng, Michael A Derby, et al.
Pageof 2